-
Intellia To Test Second CRISPR Therapeutic In Hereditary Angioedema Patients
Wednesday, October 6, 2021 - 8:29am | 364Read More...The New Zealand Medicines and Medical Devices Safety Authority (MEDSAFE) has signed off Intellia Therapeutics Inc's (NASDAQ: NTLA) Phase 1/2 study of NTLA-2002 in hereditary angioedema (HAE). NTLA-2002 is a systemically administered single-dose CRISPR / Cas9-based therapeutic...
-
NICE Recommends BioCryst's Hereditary Angioedema Med
Thursday, September 16, 2021 - 11:50am | 244Read More...The U.K.'s National Institute for Health and Care Excellence (NICE) has recommended BioCryst Pharmaceuticals Inc's (NASDAQ: BCRX) Orladeyo (berotralstat) for hereditary angioedema (HAE). The recommendation covers eligible patients 12 years and older if they have at least two...
-
FDA Lifts Clinical Hold On KalVista's Hereditary Angioedema Trial
Tuesday, September 14, 2021 - 8:20am | 323Read More...The FDA has lifted the clinical hold on KalVista Pharmaceuticals Inc's (NASDAQ: KALV) Phase 2 trial of KVD824 for oral prophylactic treatment of hereditary angioedema (HAE). Related Content: KalVista Stock Falls After FDA Institutes Clinical Hold On Hereditary...
-
BioCryst Shares 96-Week Orladeyo Data Highlighting 80% Reduction In HAE Attacks
Monday, July 12, 2021 - 7:04am | 270Read More...BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) has announced 96-week data from the Phase 3 APeX-2 trial for Orladeyo (berotralstat), showing a sustained reduction in hereditary angioedema (HAE) attacks patients. The HAE patients who were randomized to receive 150 mg of oral, once-daily...
-
BioCryst's Orladeyo Application Under Review In Israel For Hereditary Angioedema
Wednesday, June 16, 2021 - 7:50am | 130Read More...The Israeli Ministry of Health has accepted for review BioCryst Pharmaceuticals Inc's (NASDAQ: BCRX) application for Orladeyo to prevent recurrent attacks in patients with hereditary angioedema (HAE) 12 years and older. The Israeli Ministry of Health also has granted an...
-
KalVista Stock Falls After FDA Institutes Clinical Hold On Hereditary Angioedema Trial With KVD824
Tuesday, April 20, 2021 - 8:18am | 339Read More...Two months after KalVista Pharmaceuticals Inc (NASDAQ: KALV) reported positive Phase 2 results for its lead drug KVD900, an oral therapy meant to stem the effects of swelling attacks caused by the rare genetic disorder hereditary angioedema (HAE), the FDA has issued...
-
Ionis Pharma's Ligand-Conjugated Antisense Hits Primary Endpoint Goal In Hereditary Angioedema Study
Monday, March 29, 2021 - 11:30am | 250Read More...Ionis Pharmaceuticals Inc (NASDAQ: IONS) has announced data from a Phase 2 study evaluating IONIS-PKK-LRx in patients with hereditary angioedema (HAE). The study met its primary and secondary endpoints, achieving significant reductions in the number of attacks suffered by HAE...
-
BioCryst's Orladeyo Wins EU Positive Opinion For Hereditary Angioedema
Friday, February 26, 2021 - 7:31am | 275Read More...The European Medicines Agency's Committee for Orphan Medicinal Products has issued a positive opinion backing the approval of BioCryst Pharmaceuticals Inc's (NASDAQ: BCRX) ORLADEYO (berotralstat) for routine prevention of recurrent attacks of hereditary angioedema...
-
Investors Cheer Positive Data From KalVista's KVD900 Mid-Stage Hereditary Angioedema Trial
Tuesday, February 9, 2021 - 11:25am | 342Read More...Kalvista Pharmaceuticals Inc's (NASDAQ: KALV) oral plasma kallikrein inhibitor, KVD900, has reduced the use of rescue medication in patients suffering swelling attacks associated with hereditary angioedema (HAE), a disorder that results in recurrent episodes of severe...
-
BioCryst Pharmaceuticals Is Plummeting 65%
Monday, February 8, 2016 - 9:18am | 310Read More...Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) were trading lower by more than 65 percent early Monday morning after the company reported disappointing results from a clinical trial. BioCryst designs, optimizes and develops novel small molecule drugs that block key enzymes involved in...
